1. U.S.Food and Drug Administration. Hepatitis C treatments containing sofosbuvir in combination with another direct acting antiviral drug: drug safety communication - serious slowing of heart rate when used with antiarrhythmic drug amiodarone. Available at:http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm439662.htm. Accessed June 8, 2015.
2. European Medicines Agency. EMA recommends avoidance of certain hepatitis C medicines and amiodarone together. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/04/news_detail_002313.jsp&mid=WC0b01ac058004d5c1. Accessed June 8, 2015.
3. A clinician’s guide to drug-drug interactions with direct acting antiviral agents for the treatment of hepatitis C Virus Infection;Dick;Hepatology,2015
4. The P-glycoprotein transport system and cardiovascular drugs;Wessler;J Am Coll Cardiol,2013
5. Drug interactions with new hepatitis C oral drugs;Soriano;Expert Opin Drug Metab Toxicol,2015